Abstract
Adrenal or suprarenal tumours present a challenge to physicians and surgeons due to the variability in tumour type, clinical presentation and the effects of hormone secretion. A methodical approach to investigation and management is required in order to optimize outcomes and avoid the potential pitfalls that may occur with the management of these complex tumours. This chapter provides review of the investigation and management of all adrenal tumour types including adrenocortical carcinomas, phaeochromocytomas, Cushing’s and Conn’s syndrome.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Fung MM, Viveros OH, O’Connor DT. Diseases of the adrenal medulla. Acta Physiol. 2008;192(2):325–35.
Skandalakis LJ, Skandalakis JE, Skandalakis PN. Adrenal glands. In: Surgical anatomy and technique of adrenal gland. New York: Springer; 2009. p. 603–30.
Ilias I, Sahadev A, Reznik R, Grossman A, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007;14:587–99.
Sahdev A, Reznek RH. Imaging evaluation of the nonfunctioning indeterminate adrenal mass. Trends Endocrinol Metab. 2004;15:271–6.
Lockhart ME, Smith JK, Kenney PJ. Imaging of adrenalmasses. Eur J Radiol. 2002;41:95–112.
Boland GW, Dwamena BA, Jagtiani Sangwaiya M, Goehler AG, et al. Characterization of adrenalmasses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology. 2011;259:117–26.
Maurea S, Imbriaco M, Mollica C, Pace L, Salvatore M. Quantitative imaging characterization of hypersecreting or nonhypersecreting adrenal adenomas: comparison between iodine-131 norcholesterol uptake and magnetic resonance signal intensity ratios. Nucl Med Commun. 2011;32(6):535–41.
Burton TJ, Mackenzie IS, Balan K, Koo B, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol Metab. 2012;97:100–9.
Schulz C, Eisenhofer G, Lehnert H. Principles of catecholamine biosynthesis, metabolism and release. Front Horm Res. 2004;31:1–2.
Francis IR, Glazer GM, Shapiro B, Sisson JC, Gross BH. Complementary roles of CT and 131I-MIBG scintigraphy in diagnosing pheochromocytoma. AJR Am J Roentgenol. 1983;141:719–25.
Navalkissoor S, Alhashimi DM, Quigley AM, et al. Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010;37(5):904–12.
Aron D, Terzolo M, Cawood TJ. Adrenal incidentalomas. Best Pract Res Clin Endocrinol Metab. 2012;26:69–82.
Willatt JM, Francis IR. Radiologic evaluation of incidentally discovered adrenal masses. Am Fam Physician. 2010;81:1361–6.
Zeiger M, Siegelman S, Hamrahian A. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab. 2011;96:2004–15.
Hedeland H, Ostberg G, Hokfelt B. On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes. Acta Med Scand. 1968;184(3):211–4.
Garz G, Luning M, Melzer B. Computed tomographic incidental finding of a hormone-inactive adrenal cortex adenoma. Radiol Diagn (Berl). 1985;26(6):761–6.
Mantero F, Terzolo M, Arnaldi G, Osella G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85:637–44.
Allolio B. Adrenal incidentalomas. In: Chrousos GP, Margioris AN, editors. Adrenal disorders. Totowa: Humana Press Inc; 2001. p. 249–61.
Zeiger MA, Thompson GB, Duh Q-Y, et al. American association of clinical endocrinologists and American association of endocrine surgeons Medical guidelines for the management of adrenal incidentalomas. Endo Pract. 2009;15 Suppl 1:1–20.
Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med. 2003;138:424–9.
Gordon RD, Stowasser M, Tunny TJ, et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol. 1994;21:315–8.
Moreira Jr SG, Pow-Sang JM. Evaluation and management of adrenal masses. Cancer Control. 2002;9:326–34.
Kasperlik-Zeluska AA, Roslonowska E, Slowinska-Srzednicka J, et al. Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208patients. Clin Endocrinol. 1997;46:29–37.
Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16:460–84.
Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine (Baltimore). 1991;70:46–66.
Plotz C, Knowlton MAI, Ragan A. The natural history of Cushing’s syndrome. Am J Med. 1952;13:597–614.
Drake WM, Perry LA, Hinds CJ, Lowe DJ, et al. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing’s syndrome and peritonitis. J Clin Endocrinol Metab. 1998;83:3542–4.
Sbiera S, Schmull S, Assie G, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 2010;95:E161–71.
Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol. 2004;60:273–87.
Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322:1195–201.
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189–97.
Erlandson RA, Reuter VE. Oncocytic adrenal cortical adenoma. Ultrastruct Pathol. 1991;15(4–5):539–47.
Sasano H, Suzuki T, Sano T, et al. Adrenocortical oncocytoma. A true nonfunctioning adrenocortical tumor. Am J Surg Pathol. 1991;15:949–56.
Neri LM, Nance FC. Management of adrenal cysts. Am Surg. 1999;65:151–63.
Beard CM, Carney JA, Sheps SG, et al. Incidence of phaeochromocytoma. J Hum Hypertens. 1989;3:481.
Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851–6.
Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type2. International RET mutation consortium analysis. JAMA. 1996;276:1575–9.
Vargas HI, Kavoussi LR, Bartlett DL, et al. Laparoscopic adrenalectomy: a new standard of care. Urology. 1997;49:673–8.
Loh KC, Fitzgerald PA, Matthay KK, et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20:648–58.
Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. J Clin Oncol. 1998;6:1271–9.
Rosen EM, Cassady JR, Frantz CN, et al. Neuroblastoma: the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children’s Hospital experience. J Clin Oncol. 1984;2:719–32.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag London
About this chapter
Cite this chapter
Greener, V., Chew, S.L. (2015). Tumours of the Adrenal Gland. In: Nargund, V., Raghavan, D., Sandler, H. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-0-85729-482-1_25
Download citation
DOI: https://doi.org/10.1007/978-0-85729-482-1_25
Published:
Publisher Name: Springer, London
Print ISBN: 978-0-85729-481-4
Online ISBN: 978-0-85729-482-1
eBook Packages: MedicineMedicine (R0)